Development of a unique 3D interaction model of endogenous and synthetic peripheral benzodiazepine receptor ligands

Different classes of Peripheral-type Benzodiazepine Receptor (PBR) ligands were examined and common structural elements were detected and used to develop a rational binding model based on energetically allowed ligand conformations. Two lipophilic regions and one electrostatic interaction site are essential features for high affinity ligand binding, while a further lipophilic region plays an important modulator role. A comparative molecular field analysis, performed over 130 PBR ligands by means of the GRID/GOLPE methodology, led to a PLS model with both high fitting and predictive values (r2 = 0.898, Q2 = 0.761). The outcome from the 3D QSAR model and the GRID interaction fields computed on the putative endogenous PBR ligands DBI (Diazepam Binding Inhibitor) and TTN (Tetracontatetraneuropeptide) was used to identify the amino acids most probably involved in PBR binding. Three amino acids, bearing lipophilic side chains, were detected in DBI (Phe49, Leu47 and Met46) and in TTN (Phe33, Leu31 and Met30) as likely residues underlying receptor binding. Moreover, a qualitative comparison of the molecular electrostatic potentials of DBI, TTN and selected synthetic ligands indicated also similar electronic properties. Convergent results from the modeling studies of synthetic and endogenous ligands suggest a common binding mode to PBRs. This may help the rational design of new high affinity PBR ligands.

[1]  A. Guidotti,et al.  Diazepam binding inhibitor (DBI): a peptide with multiple biological actions. , 1991, Life sciences.

[2]  W. Kabsch,et al.  Dictionary of protein secondary structure: Pattern recognition of hydrogen‐bonded and geometrical features , 1983, Biopolymers.

[3]  D. E. Patterson,et al.  Crossvalidation, Bootstrapping, and Partial Least Squares Compared with Multiple Regression in Conventional QSAR Studies , 1988 .

[4]  T. Taniguchi,et al.  Structural requirements for the binding of benzodiazepines to their peripheral-type sites. , 1984, Molecular pharmacology.

[5]  H. Berendsen,et al.  COMPUTER-SIMULATION OF MOLECULAR-DYNAMICS - METHODOLOGY, APPLICATIONS, AND PERSPECTIVES IN CHEMISTRY , 1990 .

[6]  M. Menziani,et al.  Mapping the peripheral benzodiazepine receptor binding site by conformationally restrained derivatives of 1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3- isoquinolinecarboxamide (PK11195). , 1997, Journal of medicinal chemistry.

[7]  Ralph E. Christoffersen,et al.  Computer-assisted drug design , 1979 .

[8]  G. Cruciani,et al.  Generating Optimal Linear PLS Estimations (GOLPE): An Advanced Chemometric Tool for Handling 3D‐QSAR Problems , 1993 .

[9]  W. G. Hunter,et al.  Experimental Design: Review and Comment , 1984 .

[10]  R. Butterworth,et al.  Characterization of binding sites for the omega3 receptor ligands [3H]PK11195 and [3H]RO5-4864 in human brain. , 1997, European journal of pharmacology.

[11]  P. Ferrara,et al.  Molecular basis for the different binding properties of benzodiazepines to human and bovine peripheral‐type benzodiazepine receptors , 1993, FEBS letters.

[12]  P Ferrara,et al.  Site-directed mutagenesis of the peripheral benzodiazepine receptor: identification of amino acids implicated in the binding site of Ro5-4864. , 1994, Molecular pharmacology.

[13]  E. Costa,et al.  The peripheral-type benzodiazepine receptor is functionally linked to Leydig cell steroidogenesis. , 1990, The Journal of biological chemistry.

[14]  D. Williams,et al.  Peripheral-type benzodiazepine receptors. , 1997, General pharmacology.

[15]  E. Novellino,et al.  Synthesis, Biological Activity, and SARs of Pyrrolobenzoxazepine Derivatives, a New Class of Specific “Peripheral-Type” Benzodiazepine Receptor Ligands1 , 1996 .

[16]  A. Guidotti,et al.  A natural processing product of rat diazepam binding inhibitor, triakontatetraneuropeptide (diazepam binding inhibitor 17-50) contains an alpha-helix, which allows discrimination between benzodiazepine binding site subtypes. , 1990, Molecular pharmacology.

[17]  Didier Rognan,et al.  Molecular modelling :basic principles and applications , 1997 .

[18]  M Pastor,et al.  Smart region definition: a new way to improve the predictive ability and interpretability of three-dimensional quantitative structure-activity relationships. , 1997, Journal of medicinal chemistry.

[19]  A. Guidotti,et al.  2-Aryl-3-indoleacetamides (FGIN-1): a new class of potent and specific ligands for the mitochondrial DBI receptor (MDR). , 1992, The Journal of pharmacology and experimental therapeutics.

[20]  A. Guidotti,et al.  Isolation and Characterization of a Rat Brain Triakontatetraneuropeptide, a Posttranslational Product of Diazepam Binding Inhibitor: Specific Action at the Ro 5‐4864 Recognition Site , 1989, Journal of neurochemistry.

[21]  N. Bowery.  Peripheral benzodiazepine receptors: edited by Eva Giesen-Crouse, Academic Press, 1993. £45.00 (xiii + 281 pages) ISBN 0 1228 2630 2 , 1994 .

[22]  L. Kelley,et al.  An automated approach for defining core atoms and domains in an ensemble of NMR-derived protein structures. , 1997, Protein engineering.

[23]  R. Kini,et al.  Prediction of potential protein‐protein interaction sites from amino acid sequence , 1996, FEBS letters.

[24]  G. Biggio,et al.  Novel 2-phenylimidazo[1,2-a]pyridine derivatives as potent and selective ligands for peripheral benzodiazepine receptors: synthesis, binding affinity, and in vivo studies. , 1999, Journal of medicinal chemistry.

[25]  J. Swinnen,et al.  Identification of Diazepam-binding Inhibitor/Acyl-CoA-binding Protein as a Sterol Regulatory Element-binding Protein-responsive Gene* , 1998, The Journal of Biological Chemistry.

[26]  A. Toga,et al.  Journal of Cerebral Blood Flow and Metabolism Imaging Peripheral Benzodiazepine Receptors in Brain Tumors in Rats: in Vitro Binding Characteristics , 2022 .

[27]  E. Novellino,et al.  Novel ligands specific for mitochondrial benzodiazepine receptors: 6-arylpyrrolo[2,1-d][1,5]benzothiazepine derivatives. Synthesis, structure-activity relationships, and molecular modeling studies. , 1994, Journal of medicinal chemistry.

[28]  Johann Gasteiger,et al.  Multivariate structure‐activity relationships between data from a battery of biological tests and an ensemble of structure descriptors: The PLS method , 1984 .

[29]  E. Novellino,et al.  A concerted study using binding measurements, X-ray structural data, and molecular modeling on the stereochemical features responsible for the affinity of 6-arylpyrrolo[2,1-d][1,5]benzothiazepines toward mitochondrial benzodiazepine receptors. , 1995, Journal of medicinal chemistry.

[30]  P. Højrup,et al.  Amino acid sequence of acyl-CoA-binding protein from cow liver. , 1987, The Biochemical journal.

[31]  G A Petsko,et al.  Aromatic-aromatic interaction: a mechanism of protein structure stabilization. , 1985, Science.

[32]  E. Novellino,et al.  A comparative molecular field analysis model for 6-arylpyrrolo[2,1-d] [1,5]benzothiazepines binding selectively to the mitochondrial benzodiazepine receptor. , 1994, Journal of medicinal chemistry.

[33]  M. Botta,et al.  Cardiovascular characterization of pyrrolo[2,1-d][1,5]benzothiazepine derivatives binding selectively to the peripheral-type benzodiazepine receptor (PBR): from dual PBR affinity and calcium antagonist activity to novel and selective calcium entry blockers. , 1996, Journal of medicinal chemistry.

[34]  R. Cramer,et al.  Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. , 1988, Journal of the American Chemical Society.

[35]  G. Biggio,et al.  Synthesis and binding affinity of 2-phenylimidazo[1,2-alpha]pyridine derivatives for both central and peripheral benzodiazepine receptors. A new series of high-affinity and selective ligands for the peripheral type. , 1997, Journal of medicinal chemistry.

[36]  P. Goodford.  A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. , 1985, Journal of medicinal chemistry.

[37]  F. Poulsen,et al.  Three-dimensional structure in solution of acyl-coenzyme A binding protein from bovine liver. , 1992, Journal of molecular biology.

[38]  T. Langer,et al.  Molecular basis of peripheral vs central benzodiazepine receptor selectivity in a new class of peripheral benzodiazepine receptor ligands related to alpidem. , 1996, Journal of medicinal chemistry.

[39]  A. Guidotti,et al.  Endogenous ligands for high-affinity recognition sites of psychotropic drugs. , 1988, Annual review of pharmacology and toxicology.

[40]  Synthesis and pharmacological evaluation of benzofuran-acetamides as "antineophobic" mitochondrial DBI receptor complex ligands. , 1998, Bioorganic & medicinal chemistry letters.

[41]  S Ogawa,et al.  Neuropharmacological profile of peripheral benzodiazepine receptor agonists, DAA1097 and DAA1106. , 1999, Life sciences.

[42]  H. Friedman,et al.  Modulation of melphalan resistance in glioma cells with a peripheral benzodiazepine receptor ligand-melphalan conjugate. , 1997, Journal of medicinal chemistry.

[43]  P. Ferrara,et al.  The M r 18,000 Subunit of the Peripheral-type Benzodiazepine Receptor Exhibits Both Benzodiazepine and Isoquinoline Carboxamide Binding Sites in the Absence of the Voltage-dependent Anion Channel or of the Adenine Nucleotide Carrier* , 1997, The Journal of Biological Chemistry.

[44]  A. Kozikowski,et al.  Synthesis and biology of a 7-nitro-2,1,3-benzoxadiazol-4-yl derivative of 2-phenylindole-3-acetamide: a fluorescent probe for the peripheral-type benzodiazepine receptor. , 1997, Journal of medicinal chemistry.

[45]  H. Vinters,et al.  Specific high‐affinity binding of peripheral benzodiazepine receptor ligands to brain tumors in rat and man , 1990, Cancer.

[46]  M. Nishio,et al.  The CH/π interaction: Significance in molecular recognition , 1995 .